BRICKELL BIOTECH INC (BBI) Stock Price, Quote, News and Overview
NASDAQ:BBI - Nasdaq - US10802T2042 - Common Stock - Currency: USD
BBI Quote, Performance and Key Statistics
NASDAQ:BBI (9/7/2022, 8:17:32 PM)
2.35
+0.05 (+2.17%)
The current stock price of BBI is 2.35 USD. In the past month the price decreased by -35.26%. In the past year, price decreased by -93.39%.
BBI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BBI
Company Profile
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
Company Info
BRICKELL BIOTECH INC
5777 Central Ave Ste 102
Boulder COLORADO 80301 US
CEO: Robert B. Brown
Employees: 16
Company Website: https://brickellbio.com/
Phone: 17205054755.0
BRICKELL BIOTECH INC / BBI FAQ
What is the stock price of BRICKELL BIOTECH INC today?
The current stock price of BBI is 2.35 USD. The price increased by 2.17% in the last trading session.
What is the ticker symbol for BRICKELL BIOTECH INC stock?
The exchange symbol of BRICKELL BIOTECH INC is BBI and it is listed on the Nasdaq exchange.
On which exchange is BBI stock listed?
BBI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BRICKELL BIOTECH INC stock?
8 analysts have analysed BBI and the average price target is 18.19 USD. This implies a price increase of 674.04% is expected in the next year compared to the current price of 2.35. Check the BRICKELL BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRICKELL BIOTECH INC worth?
BRICKELL BIOTECH INC (BBI) has a market capitalization of 6.23M USD. This makes BBI a Nano Cap stock.
How many employees does BRICKELL BIOTECH INC have?
BRICKELL BIOTECH INC (BBI) currently has 16 employees.
What are the support and resistance levels for BRICKELL BIOTECH INC (BBI) stock?
BRICKELL BIOTECH INC (BBI) has a resistance level at 2.74. Check the full technical report for a detailed analysis of BBI support and resistance levels.
Is BRICKELL BIOTECH INC (BBI) expected to grow?
The Revenue of BRICKELL BIOTECH INC (BBI) is expected to grow by 1253.05% in the next year. Check the estimates tab for more information on the BBI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BRICKELL BIOTECH INC (BBI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BBI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BBI, evaluating the profitability, health, valuation and growth aspects
- BRICKELL BIOTECH INC (BBI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRICKELL BIOTECH INC (BBI) Sales and EPS estimates to see what analysts future expectations are.
- BRICKELL BIOTECH INC (BBI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRICKELL BIOTECH INC (BBI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRICKELL BIOTECH INC (BBI) Stock Chart to make your own analysis
- BRICKELL BIOTECH INC (BBI) Latest news and press-releases to stay up to date.
Does BRICKELL BIOTECH INC (BBI) stock pay dividends?
BBI does not pay a dividend.
When does BRICKELL BIOTECH INC (BBI) report earnings?
BRICKELL BIOTECH INC (BBI) will report earnings on 2022-11-07.
What is the Price/Earnings (PE) ratio of BRICKELL BIOTECH INC (BBI)?
BRICKELL BIOTECH INC (BBI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.7).
BBI Technical Analysis
BBI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBI. BBI has a bad profitability rating. Also its financial health evaluation is rather negative.
BBI Financial Highlights
Over the last trailing twelve months BBI reported a non-GAAP Earnings per Share(EPS) of -20.7. The EPS decreased by -1880.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8325.47% | ||
| ROA | -191.83% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BBI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BBI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 70.65% and a revenue growth 1253.05% for BBI